Hib-DTaP-poliovirus vaccine - Baxter International

Drug Profile

Hib-DTaP-poliovirus vaccine - Baxter International

Alternative Names: Certiva-IPV-Hib; Hib-DTP-acellular-poliovirus vaccine - North American Vaccine

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International; Statens Serum Institut
  • Developer Baxter International
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 16 Jan 2017 Statens Serum Institut sold its vaccine production business to AJ Vaccines
  • 21 Sep 2006 Discontinued - Preclinical for Diphtheria in USA (Injection)
  • 21 Sep 2006 Discontinued - Preclinical for Haemophilus infections in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top